Epoprostenol (Flolan, Veletri)

Epoprostenol (Flolan, Veletri) is covered only for FDA‑approved use to improve exercise capacity in pulmonary arterial hypertension (WHO Group I) and excludes all off‑label/compendial uses and PAH etiologies other than idiopathic, heritable, or connective tissue disease‑associated, as well as patients with NYHA class I–II, heart failure with reduced LVEF, or pulmonary edema. Approval requires right heart catheterization confirmation of WHO Group I PAH, documentation of NYHA functional class III or IV, and documentation that the patient does not have HF from reduced LVEF or pulmonary edema and has one of the specified etiologies.

"Epoprostenol injection is indicated for the treatment of pulmonary arterial hypertension (World Health Organization [WHO] Group I) to improve exercise capacity."

Sign up to see full coverage criteria, indications, and limitations.